IL10 and colitis: In conclusion, this study provides initial evidence that the systemic delivery of Bry‐1 ameliorates spontaneous colitis in Il‐10−/− mice, and this effect is associated with the attenuation of intestinal barrier injury and the abnormal intestinal mucosal immune response.